Table 1.
Anti-MUC1 antibodies and MUC1 (CA 15.3) levels in benign and malignant gynecological diseases.
| Study population | N 652 | MUC1 IgG (Arb.U/mL) Median (range) | MUC1 IgM (Arb.U/mL) Median (range) | CA 15.3 (U/mL) Median (range) | CA 15.3 P* |
|---|---|---|---|---|---|
| Healthy controls | 125 | 0.95 (0.43–5.70) | 2.7 (0.96–15.78) | 17 (1–48) | |
| Controls with CIN lesions of the cervix | 134 | 1.04 (0.51–5.58) | 3.09 (1.08 –12.03) | 17 (4–54) | |
| Endometriosis | 26 | 0.73 (0.41–7.26) | 2.94 (1 –8.85) | ||
| Benign ovarian tumors | 102 | 1.23 (0.40–20.49) | 2.73 (0.79–15.22) | 15 (5–50) | n.s. |
| Borderline ovarian tumors | 10 | 1.28 (0.37–3.41) | 2.16 (0.70–9.22) | 16 (5–24) | n.s. |
| Ovarian carcinoma | 113 | 1.19 (0.36–7.11) | 1.92 (0.51–9.91) | 44 (5–1282) | <0.001 |
| - Stage I | 25 | 1.12 (0.50–4) | 2.23 (0.68–9.21) | 25 (5–350) | |
| - Stage II | 14 | 0.84 (0.36–2.09) | 2.35 (1.02–8.30) | 28 (9–166) | |
| - Stage III | 56 | 1.29 (0.61–7.11) | 1.78 (0.51–9.91) | 58 (9–1282) | |
| - Stage IV | 20 | 1.37 (0.48–2.98) | 1.89 (0.63–4.66) | 71 (8–1067) | |
| Endometrial carcinoma | 29 | 1.22 (0.61–2.48) | 1.81 (0.67–9.33) | 21 (5–65) | n.s. |
| Adenocarcinoma of the cervix | 18 | 0.67 (0.15–2.85) | 2.48 (1.07–15) | ||
| Squamous cell carcinoma of the cervix | 95 | 0.92 (0.42–13.58) | 2.92 (1.03–10.26) | 18 (4–117) | 0.002¶ |
*
Mann-Whitney U test, CA 15.3 levels in each group compared to levels in healthy controls.
¶
Mann-Whitney U test, CA 15.3 levels compared to levels in controls with CIN lesions.